Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 67

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 67
---
 annual cash bonus opportunity for 2024 and the corporate objectives for 2024, and (c) their annual stock option award for 2024.

In the case of Dr. Kinney, after discussion with a senior member of management and Pay Governance, the Committee recommended to the Board his base salary, his annual cash bonus opportunity for fiscal year 2024 and the 2024 corporate objectives upon which that bonus opportunity would be based, and his annual stock option award. In an executive session without Dr. Kinney present, the Board considered, discussed, and approved the compensation recommended by the Committee with respect to Dr. Kinney.

After completion of fiscal year 2024, the Committee received management’s report on the Company’s performance relative to the pre-established corporate objectives for 2024, and Dr. Kinney, and our Chief People Officer, Chief Legal Officer, and another senior member of management discussed such report and presented their assessments and recommendations with the Committee. Dr. Kinney presented on and discussed the individual performance of each executive officer, provided that Dr. Kinney did not make recommendations as to his own compensation nor participate in discussion with the Committee regarding his own compensation. Pay Governance participated in discussions with the Committee. After receiving that report, and assessment and recommendations from management, the Committee determined the annual cash bonus to be paid to each executive officer other than Dr. Kinney for 2024.

After completion of fiscal year 2024, the Nominating and Corporate Governance Committee of the Board completed a review of Dr. Kinney’s performance during 2024 (with input from all other independent members of the Board) and this review was reported to both the Compensation Committee and the Board. The Compensation Committee also met in executive session with Pay Governance to discuss Dr. Kinney’s compensation. The Committee determined and recommended to the Board (other than Dr. Kinney) Dr. Kinney’s annual cash bonus for 2024 based on attainment of pre-established corporate objectives for 2024. In an executive session without Dr. Kinney present, the Board considered, discussed, and approved the bonus amount recommended by the Committee.

Equity Grant Practices and Procedures. All stock options awarded to our executive officers other than the Chief Executive Officer are approved by the Committee, and stock options awarded to our Chief Executive Officer are approved by our Board (based

| 40 |     | 2025 PROXY STATEMENT |

TABLE OF CONTENTS

| COMPENSATION DISCUSSION AND ANALYSIS |

on recommendations from the Committee